• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

RNA Vaccine Patent Landscape 2021: mRNA as Vaccines Won the Race for the COVID-19 Vaccine

Research and Markets Logo

News provided by

Research and Markets

Mar 10, 2021, 08:00 ET

Share this article

Share this article


DUBLIN, March 10, 2021 /PRNewswire/ -- The "RNA Vaccine Patent Landscape 2021" report has been added to ResearchAndMarkets.com's offering.

RNA vaccines represent a major challenge for the pharmaceutical industry

The idea of using mRNA as vaccines has been investigated for nearly three decades. By winning the race for a Covid-19 vaccine, mRNA vaccines have proven their worth, and it has highlighted their advantages over conventional vaccines. Now, all major pharmaceutical companies are, in some way, testing out the technology by entering into license agreements and/or collaboration with well-established RNA companies (Pfizer, Sanofi, AstraZeneca, GSK, Merck, Roche, Bayer, etc.).

Now that the first products have arrived on the market, IP positions have to be defined as companies will enforce their patents to secure their positions on the market. Patent litigations have already been initiated before the EPO and the USPTO against key patents. Over 30 opposition proceedings have been identified herein, most of which were filed in the past 2 years and still pending. In this context, Arbutus recently succeeded in maintaining one of its key US patents covering its LNP delivery system, that could potentially cover Moderna's RNA vaccine.

However, as Moderna already announced, it is unlikely that patents will be enforced during the pandemic. The speed at which an mRNA vaccine can be designed has been the key to the recent success. Indeed, the first batches for human testing were made in less than 2 months, and authority approvals were granted in less than a year. Clinical trials have demonstrated their safety and efficacy on mRNA vaccine candidates (about 95% effective in preventing COVID-19).

Beyond a COVID-19 vaccine, RNA technology holds high promise for new vaccines against cancer and challenging viruses that conventional vaccines have failed to address (e.g. HIV, HSV, RSV). Moreover, this emerging technology successfully triggers antigen-specific T cell responses in cancer therapy. It also allows personalized immunotherapy by matching the genetic profile of each person's cancer and inducing an immune response against the mutated part of the tumors (cancer neoantigen vaccines). In this evolving context, it is crucial to understand the intellectual property position and strategy of these different players. Such knowledge can help detect business risks and opportunities, anticipate emerging technologies, and enable strategic decisions to strengthen market position.

The first patent family identified was published in 1990. However, the technology was in a maturation phase up to 2010, as evidenced by a relatively low number of patent publications. This maturation phase was mostly related to the problem of rapid naked RNA degradation and the delivery system. One of the key discoveries that allowed the mRNA vaccine field to expand was based on research by Kariko et al. (2005 and 2008) on the incorporation of modified nucleoside into mRNA to increase stability and to ablate the mammalian innate immune response through the activation of Toll-like receptors (patented technology filed by the Trustees of the University of Pennsylvania). The other key discovery was the use of lipid particles to protect and deliver the RNA molecule into the cells (patented by Protiva Therapeutics, now Arbutus Biopharma). The combination of these two discoveries allowed the field to expand, with an approximate 9-fold increase in patent publications between 2009 and 2020.

Analysis by segment

Patent families identified in the report are primarily disclosed mRNA vaccines for the treatment of infectious diseases and cancer, RNA delivery systems, and methods of stabilizing the RNA molecules for optimizing translation and half-life (chemical and non-chemical modifications; optimized sequences, cap structure, poly(A) tail, 3' and 5' UTR, ORF). For each segment, the patent publication timeline, patenting strategy and patent portfolios of top players have been analyzed. The present IP landscape features the following technological segmentation:
Infectious diseases: The main RNA players already have numerous RNA vaccines in development against various viruses, e.g. COVID-19, Influenza virus, Ebola virus, Marburg virus, Zika virus, Rabies virus, cytomegalovirus, HIV, Yellow fever and others.

Cancer: mRNA cancer vaccine targets include Tumor-Associated Antigens (TAA) or neoantigens (antigens derived from genetic alterations and are tumor-specific). The latest in particular provided promising results as it allows personalized immunotherapy by inducing an immune response against the mutated part of the tumors.

RNA delivery: RNA vaccines rely on a delivery vehicle for efficient cellular uptake and degradation protection. Lipid nanoparticles is now the method of choice for encapsulating and delivering RNA vaccines.

RNA modification/stabilization: Studies directed to 5' and 3' UTR regions, 5' cap, poly (A) tail, codon or nucleotides have proven essential to enhance the RNA stability/half-life and translation efficiency of the mRNA molecule.

Identifying the key companies and newcomers in the IP landscape

Among the players that have filed patents related to RNA vaccines, over 10 newcomers were identified. These companies are established companies developing their first products in the RNA vaccine sector. Most IP newcomers are based in the US and Europe, while only two were identified in Asia. Many mRNA companies identified have already entered into partnerships to advance their broader vaccine development programs through license agreements and/or joint research. The present report identifies numerous jointly filed patent families resulting from such collaboration, as well as press releases disclosing licensed agreements. Moreover, patent assignment analysis reveals players entering the field through the acquisition of patent families.

Key patent analysis

This IP study includes the selection and description of key patents. The key patent analysis includes the family's legal status for each of the main territories, the number of received citations, the review of the main claim(s) (European and/or US claims), a description of interesting features of the innovation disclosures and relevant figures illustrating how the innovation works. The report also contains information about opposition in Europe.

Excel database

Moreover, the report also includes an Excel database with the >480 patent families analyzed in this study. This useful patent database allows for multi-criteria searches and includes patent publication numbers, hyperlinks to the original documents, priority dates, titles, abstracts, patent assignees and segmentation. The Excel database also includes hyperlinks to an updated online database (legal status, documents etc.) for each selected patent family.

Report's Key Features

  • PDF with > 100 slides
  • Excel file > 480 patent families + hyperlink to updated online database (legal status, documents etc.)
  • IP trends, including time-evolution of published patents, and countries of patent filings
  • Ranking of main patent assignees
  • Key players' IP position and relative strength of their patent portfolios
  • Summary of the IP related to applications: Infectious Diseases and Cancer therapy.
  • Summary of the IP related to technologies: RNA Delivery and RNA modifications.
  • Analysis of patent oppositions (Europe) and review of key patents

Companies Mentioned

  • Acuitas Therapeutics
  • Alnylam Pharmaceuticals
  • Arbutus Biopharma
  • Arcturus Therapeutics
  • Astellas
  • Biontech
  • Curevac
  • Etherna
  • GlaxoSmithKline
  • Moderna
  • Morphogenesis
  • PCI Biotech
  • Translate Bio
  • Tron
  • Vaccibody

For more information about this report visit https://www.researchandmarkets.com/r/5z4oc8

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Modal title

Also from this source

US Oil and Gas Burner Management System Market Report 2022:...

US Oil and Gas Burner Management System Market Report 2022:...


Global Opioids Market to 2027 - Size, Share & Industry Trends ...

Global Opioids Market to 2027 - Size, Share & Industry Trends ...

Explore

More news releases in similar topics

  • Publishing & Information Services
  • Pharmaceuticals
  • Health Care & Hospitals
  • Medical Pharmaceuticals
  • Surveys, Polls and Research

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.